Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysis

BACKGROUND/AIM: Presently, there are no therapeutic options for unresectable hepatocellular carcinoma (u‐HCC) patients who are intolerant to sorafenib or regorafenib failure. There have been no reports with detailed clinical findings of lenvatinib (LEN), a newly developed first‐line tyrosine kinase...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancer Med
Главные авторы: Hiraoka, Atsushi, Kumada, Takashi, Kariyama, Kazuya, Takaguchi, Koichi, Atsukawa, Masanori, Itobayashi, Ei, Tsuji, Kunihiko, Tajiri, Kazuto, Hirooka, Masashi, Shimada, Noritomo, Shibata, Hiroshi, Ishikawa, Toru, Ochi, Hironori, Tada, Toshifumi, Toyoda, Hidenori, Nouso, Kazuhiro, Tsutsui, Akemi, Itokawa, Norio, Imai, Michitaka, Joko, Kouji, Hiasa, Yoichi, Michitaka, Kojiro
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2018
Предметы:
Clinical Cancer Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6346240/
https://ncbi.nlm.nih.gov/pubmed/30575325
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1909
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы